🇺🇸 VX-659 in United States

15 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 15

Most-reported reactions

1. Alanine Aminotransferase Increased — 2 reports (13.33%)
2. Aspartate Aminotransferase Increased — 2 reports (13.33%)
3. Gamma-Glutamyltransferase Increased — 2 reports (13.33%)
4. Pneumonia Pseudomonal — 2 reports (13.33%)
5. Vomiting — 2 reports (13.33%)
6. Bile Duct Stone — 1 report (6.67%)
7. Blood Bilirubin Increased — 1 report (6.67%)
8. Cholangitis — 1 report (6.67%)
9. Cholecystitis — 1 report (6.67%)
10. Cholelithiasis — 1 report (6.67%)

Source database →

Frequently asked questions

Is VX-659 approved in United States?

VX-659 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for VX-659 in United States?

Vertex Pharmaceuticals Incorporated is the originator. The local marketing authorisation holder may differ — check the official source linked above.